The conventional drug susceptibility tests for Mycobacterium tuberculosis are timeconsuming and the results are available only after 2-4 weeks. We have recently reported a new, simple and fast M. tuberculosis drug susceptibility test, using the hybridization protection assay (HPA), that allows the detection of isoniazid-or rifampicin-resistant strains of M. tuberculosis within 24 h of incubation. In the present study, the scope of application of our new test was extended to another two first-line antimycobacterial agents, namely ethambutol and streptomycin, and a quinolone antimicrobial agent, ciprofloxacin. The ethambutol-, streptomycin-and ciprofloxacin-resistance characteristics of M. tuberculosis were also delineated within 72 h of incubation with or without the drug. The results of our novel and rapid drug susceptibility test for M. tuberculosis were not only comparable to those determined by the conventional method, but became available within a few days of incubation. Our results also suggest that the drug susceptibility test using HPA might also be useful for detecting organisms resistant to antimicrobial agents other than antimycobacterials.
Introduction
In recent years, new laboratory and clinical methods designed to detect or identify mycobacteria have been developed applying molecular biological techniques. However, currently available drug susceptibility tests for Mycobacterium tuberculosis are time-consuming and the results are not usually available for 2-4 weeks. The hybridization protection assay (HPA), which was originally developed to identify mycobacteria, has recently been used as a rapid drug susceptibility test for M. tuberculosis. 1 Our results showed that the number of viable bacteria during the incubation period correlated well with the number of relative light units (RLU) measured by the HPA. In addition, the RLU values of susceptible strains on the first, third and fifth days of incubation were significantly different from those of resistant strains for both isoniazid and rifampicin, indicating that the test was fast and accurate in identifying M. tuberculosis strains resistant to isoniazid or rifampicin. On this basis the study was extended by applying the HPA drug susceptibility test to the rapid detection of resistance to another two first-line antituberculous agents, namely ethambutol and streptomycin, and a quinolone antimicrobial agent, ciprofloxacin.
Materials and methods

Organisms
Seventeen clinical isolates of M. tuberculosis were collected from Nagasaki University Hospital and affiliated hospitals. They were divided into six groups according to the MICs of ethambutol, streptomycin or ciprofloxacin, determined by a conventional method described below. These groups included ethambutol-susceptible strains with MICs of 2.5 mg/L, ethambutol-resistant strains with MICs of 5 mg/L, streptomycin-susceptible strains with MICs of 2 mg/L, streptomycin-resistant strains with MICs of 10 mg/L, ciprofloxacin-susceptible strains with MICs of 1 mg/L and ciprofloxacin-resistant strains with MICs of 5 mg/L. Each isolate of M. tuberculosis was initially cultured on Ogawa egg medium. For the in-vitro drug susceptibility test, Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI, USA), supplemented with 100 mL of Middlebrook OADC enrichment (Difco) and 0.05% Tween 80 per litre, was used for the microdilution and rapid HPA methods. Middlebrook 7H10 agar (Difco) supplemented with 100 mL of Middlebrook OADC enrichment and 0.5% glycerol per litre, was used to measure the number of viable bacteria in representative strains ofethambutol-, streptomycin-and ciprofloxacin-susceptible and -resistant strains.
Determination of MICs
The broth microdilution method was used to determine the MIC of ethambutol, streptomycin and ciprofloxacin for M. tuberculosis. [2] [3] [4] Briefly, 50 L of serial two-fold dilutions of each antimicrobial agent solution, ranging from 0.125 mg/L to 1024 mg/L, were dispensed into 96-well plates (Corning 2580, Iwaki Glass Co., Chiba, Japan). One to three colonies previously grown on Ogawa egg agar were inoculated into 10 mL of Middlebrook 7H9 broth and incubated at 37°C for 1 week. The inocula were adjusted to the density of McFarland standard no. 0.5, and 50 L of the suspension was added to each well. The final concentrations of the antimicrobial agents ranged from 0.063 to 512 mg/L. The plates were then covered with lids and incubated at 37°C. The MICs were determined with a reading stand equipped with a mirror after 7-21 days of incubation, when successful mycobacterial growth was observed in the drug-free wells. The MIC was defined as the lowest concentration of the antimicrobial agent at which the organism showed no visible growth.
Drug susceptibility test using HPA
The appropriate density of mycobacterial suspensions for the susceptibility test using HPA was previously determined in a series of preliminary experiments. 1 The HPA susceptibility test was performed as follows. The strain grown on Ogawa egg medium was inoculated into Middlebrook 7H9 broth and cultured at 37°C for 5-7 days. The inocula were prepared by ten-fold dilution of a bacterial suspension equivalent to a McFarland no. 0.5 standard. Then, the inoculum was mixed with an antimicrobial agent solution to prepare final concentrations of 2.5 and 5 mg/L for ethambutol, 2 and 10 mg/L for streptomycin, and 1 and 5 mg/L for ciprofloxacin. The resulting bacterial suspension with or without the test drug was cultured on an agitated plate at 37°C for up to 5 days. On days 0, 1, 3 and 5 (days 0, 3 and 5 for ciprofloxacin) samples were removed and used for the HPA protocol with an acridinium-ester (AE)-labelled DNA probe (AccuProbe, Gen-Probe, Inc., San Diego, CA, USA). 5, 6 For this purpose, 50 L of each sample was sonicated in a lysing reagent tube containing glass beads and buffer solution in a sonication bath (Bransonic ultrasonic cleaner, model B2200, Emerson, Tokyo, Japan) for 20 min; the mixture was then heated at 95°C for 10 min. In the next step, 100 L of each lysate was incubated for 15 min at 60°C in a water bath with the reconstituted lyophilized DNA probe. Then, 300 L of a selection reagent (borate buffer solution containing surfactant) was added, and the mixture was incubated at 60°C for 5 min to allow the differentiation of nonhybridized and hybridized AE-labelled DNA probe. After incubation at room temperature for 5 min, the assay results were read on a luminometer (Leader 50, Gen-Probe) and expressed as RLU. Each suspension was assayed in duplicate for hybridization, and the results were expressed as the average of the two readings. The RLU ratio was calculated by dividing the RLU measured on day 1, 3 or 5 by that measured on day 0, and represented the change in RLU value in each strain tested. Differences in RLU ratios between groups with and without antimicrobial agents were compared using Student's t-test, and statistical significance was set at P 0.01.
Simultaneously, the concentrations of viable mycobacteria in each suspension of representative susceptible and resistant strains for ethambutol, streptomycin and ciprofloxacin were determined. The viable bacterial count was performed by withdrawing 500 L of each sample followed by serial ten-fold dilutions (10 1 to 10 5 ) in Middlebrook 7H9 broth. Then, 100 L of each sample was inoculated on Middlebrook 7H10 agar. Two to four weeks later, the number of colonies was counted and the concentration of viable mycobacteria was calculated.
Results
MICs of ethambutol, streptomycin and ciprofloxacin against tested organisms
M. tuberculosis strains were classified as follows (MIC in parentheses, mg/L). Five ethambutol-susceptible strains: U106 (2), U107 (2), U111 (2), U112 (2) and U115 (2), four ethambutol-resistant strains: U113 (16), N128 (16), K137 (128) and K139 (16), five streptomycin-susceptible strains: U106 (0.5), U107 (1), U112 (1), U115 (0.25) and U118 (0.25), five streptomycin-resistant strains: U108 (64), U113 ( 512), N128 ( 512), K137 ( 512) and K139 ( 512), five ciprofloxacin-susceptible strains: U106 (0.25), U107 (0.25), U112 (0.25), U113 (0.125) and U122 (0.25), and five ciprofloxacin-resistant strains: T101 (16), N132 (8), K136 (8), K138 (32) and K140 (8) .
Drug susceptibility test using HPA
The average RLU ratio of cultures of ethambutolsusceptible strains incubated with ethambutol was significantly different from that of cultures of the same strains that did not contain ethambutol. The difference was observed as early as the third day of incubation (Figure 1a) . In contrast, there was no difference in the RLU ratio between cultures of ethambutol-resistant strains incubated with and without ethambutol (Figure 1b) . The effect of ethambutol on viable bacterial count in a representative ethambutol-susceptible strain (U106) and ethambutolresistant strain (U113) was also examined. A remarkable reduction in viable bacterial count was observed in U106 strain after 3-and 5-day incubation with ethambutol ( Figure 1c ). In contrast, there was no difference between counts of U113 strain cultured with and without ethambutol during the incubation period (Figure 1d ). These results indicated that the changes in viable bacterial count correlated well with those of the RLU ratio. Similarly, significant differences in the RLU ratio during a 5-day incubation period were observed in streptomycin-susceptible strains between cultures prepared with or without streptomycin, but no difference in streptomycin-resistant strains was observed (Figure 2a and b) . Changes in the number of viable bacteria in a representative streptomycinsusceptible strain (U107) and streptomycin-resistant strain (N128) correlated well with those of RLU ratio, similar to our findings in ethambutol (Figure 2c and d) . A similar pattern was also observed in ciprofloxacin cultures. Thus, a significant difference in the average RLU ratio between cultures of ciprofloxacin-susceptible strains incubated with and without ciprofloxacin was observed after a 3-day incubation period (Figure 3a) . In comparison, no difference in the RLU ratio between cultures of ciprofloxacin-resistant strains incubated with and without ciprofloxacin was observed (Figure 3b ). In addition, changes in the number of viable bacteria for each representative ciprofloxacinsusceptible strain (U106) and ciprofloxacin-resistant strain (N132) in the presence and absence of ciprofloxacin correlated well with those of the RLU ratio (Figure 3c and d).
Discussion
Several new drug susceptibility tests for M. tuberculosis have been developed recently. [7] [8] [9] [10] [11] [12] [13] In particular, applying molecular biological techniques, new methods using the Gen-Probe DNA hybridization system, 14 luciferase 15, 16 and amplification of rRNA 17 have been reported in the last few years. The majority of these methods, however, remain unavailable commercially, and their use is limited because of the involvement of radioactive material. We have reported recently a new, simple and fast M. tuberculosis drug susceptibility test using a safe, commercially available and easy identification HPA kit using DNA probe hybridization with rRNA of mycobacteria. 1 In that study, we demonstrated an excellent relationship between viable bacterial counts and RLU values, i.e. changes in the RLU value exactly reflected those of viable bacterial counts. In addition, when isoniazid or rifampicin was added to the mycobacterial culture broth, a similar excellent correlation between the number of viable bacteria and RLU value was also noted. Consequently, since differences between RLU ratios of isoniazid-or rifampicin-susceptible and -resistant strains and the ratios under drug-free conditions were observed during 1-5 day incubations, the characteristics of the tested resistant strains of M. tuberculosis were confirmed within the first 24 h of incubation with the drug, following culture and isolation of the organism.
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In the present study, the scope of our early work was extended to test another two first-line antituberculous agents, namely ethambutol and streptomycin, and a quinolone antimicrobial agent, ciprofloxacin. A similar significant correlation between viable bacterial counts and RLU values was demonstrated even when the incubation was with ethambutol, streptomycin or ciprofloxacin as well as with isoniazid or rifampicin. Differences between RLU ratios of drug-susceptible and -resistant strains and the ratios under drug-free conditions were also observed during 3-5 day incubation periods (as early as 1 day incubation for streptomycin).
Ciprofloxacin is used for the treatment of multi-drug resistant M. tuberculosis infection because of its excellent antimycobacterial activity, so the in-vitro activity of ciprofloxacin against M. tuberculosis is important clinical information. The MIC 90 of ciprofloxacin against M. tuberculosis has been reported in several studies and ranged from 0.25 to 2 mg/L. [18] [19] [20] Other studies have shown that the sputum concentration of ciprofloxacin was about 3 mg/L when the drug was administered in a 750 mg oral dose. 21 Although the clinical breakpoint of MIC for the treatment of patients with tuberculosis has not been defined, it was shown in our study that our new method can accurately establish the resistance characteristics of the mycobacteria using a breakpoint determined from the bacteriological MIC and pharmacokinetics in the sputum.
Our novel drug susceptibility test of M. tuberculosis not only correlated well with the conventional method but produced the desired results within 3 days of incubation. The results also suggest that the drug susceptibility test using HPA might also be useful to detect resistance to antimicrobial agents other than antimycobacterials, even in the ordinary routine laboratory.
